Digital Transformation

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.

Otsuka/Click’s global-first adjunctive digital therapy for depression marks another step by pharmaceutical firms going digital for psychotherapy through collaborations.

Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.

South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.

In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.

Machines are now generating molecules that “no human would have imagined,” heard delegates at the BioAsia 2024 summit in Hyderabad, as big pharma and tech leaders discussed the many ways in which AI is causing fundamental shift in R&D approaches.

In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.

The former Bayer research head needs to turn the AI-based company around, but investors are skeptical about its attempts to serve big pharma and develop its own pipeline simultaneously.

Bristol Myers Squibb’s EVP and chief digital and technology officer, Greg Meyers, tells Scrip how the company is using data, technology and artificial intelligence to speed up the clinical research process. An AI engine that leverages real-world data to improve trial diversity and promising generative AI uses cases are some of the key topics discussed.

A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.

Soon-to-start digital transformation initiatives at the major Japanese pharma firm will focus on in-housing of IT systems and company-wide enhancement of AI/data analytics skills.

The sacking of CEO Andrew Hopkins over inappropriate relationships with two employees has cast a cloud over the high-profile AI biotech.

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

In this week's podcast edition of Five Must-Know Things: the biggest drug launches expected in 2024; Roche’s Pharma CEO talks about growth momentum; 10 pivotal studies to look out for this year; the obesity market now and in future; and what does 2024 hold for transformative technology in biopharma.